Effects of Chemoradiotherapy on PD-L1 Expression in Esophageal Cancer
Author Information
Author(s): Hampe Lovis, Küffer Stefan, Niemeier Tim, Scheele Niklas Christian, Hampe Laetitia Zoe, Riedl Anna Luisa, Fischer Laura Anna, Ziegler David Alexander, Leu Martin, Dröge Leif Hendrik, König Alexander, Ghadimi Michael, Braulke Friederike, Rieken Stefan, Bohnenberger Hanibal, El Shafie Rami A.
Primary Institution: University Medical Center Göttingen, Göttingen, Germany
Hypothesis
Does neoadjuvant chemoradiotherapy affect PD-L1 expression in esophageal cancer?
Conclusion
Neoadjuvant chemoradiotherapy does not significantly induce PD-L1 expression in vivo in esophageal cancer patients.
Supporting Evidence
- PD-L1 expression was upregulated by Carboplatin and CRT in all tested cell lines.
- KYSE-180 cell line showed the highest relative increase in PD-L1 expression.
- Transient upregulation of PD-L1 was observed, peaking at 72 hours post-treatment.
- Only 37% of patients showed a relevant change in PD-L1 expression after neoadjuvant CRT.
- Most patients had unchanged or decreased PD-L1 scores post-treatment.
Takeaway
This study looked at how certain cancer treatments affect a protein called PD-L1 in esophageal cancer. It found that while treatments can increase PD-L1 in lab tests, this doesn't happen in real patients after treatment.
Methodology
The study assessed PD-L1 expression in esophageal cancer cell lines and patient samples using flow cytometry and immunohistochemistry.
Potential Biases
Potential bias in patient selection and the retrospective design may affect the results.
Limitations
The study's findings may not be applicable to all patients due to the small sample size and the retrospective nature of the analysis.
Participant Demographics
19 patients with esophageal cancer (9 EAC, 10 ESCC) treated with neoadjuvant CRT.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website